Top Growth Trends in the Preeclampsia Drugs Market: Insights into Market Size and Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What External and Internal Drivers Are Contributing to the Growth of thePreeclampsia Drugs Market?
The anticipated increase in cases of diabetes in expectant women is believed to stimulate the expansion of the preeclampsia drug market. Diabetes, a long-term metabolic illness distinguished by elevated levels of blood glucose or blood sugar, is often linked to preeclampsia, a dangerous prenatal condition that results in high blood pressure and organ harm. Metformin, a drug used to treat preeclampsia, is commonly utilized in cases of early-onset preeclampsia among pregnant women. For instance, the National Library of Medicine, an American biomedical library and biomedical informatics hub, reported that there were 20,865 incidences of gestational diabetes mellitus (GDM) in December 2022, a jump of 6.56% that year. Consequently, the upward trend in diabetes instances among pregnant women is thought to fuel the preeclampsia drug market. The escalating occurrence of lifestyle diseases is another factor projected to boost the preeclampsia drug market’s growth. Lifestyle diseases, otherwise known as non-communicable diseases (NCDs), encompass health problems majorly caused by unhealthy lifestyle behaviors and choices. Pharmaceuticals for preeclampsia are employed to manage lifestyle diseases such as hypertension, obesity, and diabetes, all of which are risk factors for preeclampsia. For instance, according to the World Health Organization, 74% of the 41 million annual deaths globally, a significant number reported in September 2022, resulted from NCDs or chronic conditions. Among these, cardiovascular diseases accounted for 17.9 million deaths, cancer for 9.3 million, chronic respiratory diseases for 4.1 million, and diabetes for 2.0 million. Therefore, the increasing prevalence of lifestyle ailments is propelling the preeclampsia drug market’s growth.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp
What is the Predicted Annual Growth Rate of thePreeclampsia Drugs Market Impact Industry Trends by 2034?
The market size for preeclampsia drugs has expanded dramatically in the past few years. It’s forecasted to rise from $1.25 billion in 2024 to $1.38 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.6%. Factors contributing to the growth during the historical period include heightened awareness about maternal health, investments in research and development, concerns over neonatal health, and earlier detection.
It is anticipated that the market for preeclampsia drugs will expand rapidly in the upcoming years, reaching a valuation of $2.12 billion by 2029 with a CAGR of 11.3%. This predicted progression during the forecast period can be traced back to factors such as personalized treatments, non-invasive diagnostic methods, targeted interventions, and initiatives aimed at health equality. Key trends expected to emerge within this period include proactive measures, a focus on patient-centric care, consistent monitoring, and regulatory attention.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13025
Which Upcoming Market Trends and Innovations Are Set to Influence thePreeclampsia Drugs Market’s Path Forward?
Leading entities in the preeclampsia medicine market are striving to develop innovative drug solutions to strengthen their market standing. Comanche Biopharma Corp., a biopharmaceutical company based in the US, announced in March 2023 that its medicinal product, CBP-4888, which is a unique siRNA treatment for preeclampsia, received Food and Drug Administration (FDA) approval for an Investigational New Drug (IND) application. CBP-4888 is a subcutaneously administered siRNA therapy that minimizes the production of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. It mainly combats preeclampsia, triggered by the placenta’s excessive production of the protein sFLT1, which enters the mother’s bloodstream. CBP-4888 has the potential to lessen preeclampsia symptoms, including elevated blood pressure and organ damage, possibly facilitating the safe prolongation of pregnancy.
Who Are the Dominant Market Players Pushing the Boundaries of thePreeclampsia Drugs Market?
Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report
What Are the Core Segments of the Preeclampsia Drugs Market, and How Do They Contribute to Growth?
The preeclampsia drugs market covered in this report is segmented –
1) By Type: Mild Preeclampsia, Severe Preeclampsia
2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Mild Preeclampsia: Blood Pressure Management, Proteinuria Monitoring, Lifestyle Modifications
2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy, Emergency Delivery Management
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13025&type=smp
What Regions Are Dominating the Preeclampsia Drugs Market Growth?
North America was the largest region in the preeclampsia drugs market in 2024. The regions covered in preeclampsia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Reports Similar to the Global Preeclampsia Drugs Market 2025, By The Business Research Company:
Female Fertility And Pregnancy Rapid Test Global Market Report 2024
Fertility Treatments Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report
Hormonal Contraceptives Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
